# Memorial Sloan Kettering Cancer Center: Phase 1 study completed, 20 enrolled (Multiple Myeloma)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Sponsor type | Academic and hospital |
| Study | BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma |
| NCT ID | NCT03070327 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Multiple Myeloma |
| Intervention types | biological, drug |
| Target enrollment | 20 |
| Site countries | United States |
| Posted | 2017-03-03 |
| Planned start | 2017-02-27 |
| Event | Completed |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-07 |

## Why this score
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03070327). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.